Number of participants with all cause adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, and number of participant deaths.

AEs and laboratory values will be graded according to the NCI CTCAE version 4.03.

All Treated Participants

Number of Participants with laboratory abnormalities in specific thyroid tests.

TSH = Thyroid stimulating hormone ULN = Upper limit number LLN = Lower limit number

All treated participants with at least one on - treatment TSH measurement

Number of Participants with laboratory abnormalities in specific liver tests.

ALT = alanine aminotransferase AST = aspartate aminotransferase ALP = alkaline phosphatase

All treated participants with at least one on - treatment liver test measurement

BOR will be defined by CR, PR, PD and SD

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

All treated participants

Defined as the percentage of all treated participants whose BOR is either a complete response(CR) or partial response(PR).

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

All treated participants

The time from the first dosing date to the date of first objectively documented disease progression or death due to any cause, whichever occurs first.

Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

All treated participants with evaluable PFS measures

All treated participants with a BOR of CR or PR, is defined as the time between the date of first response and the date of disease progression or death, whichever occurs first.

Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.

Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

All treated participants with a CR or PR

Number of participants with a positive Anti-Drug Antibody to BMS-986156 or nivolumab

All BMS-986156 or Nivolumab Treated participants with Baseline and at Least One Post-baseline Assessment